RxDoctor Payments Data

Krizia Daniels, APRN

Adult Health · Hudson, FLNPI 1598303851

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 52 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$726
  • AstraZeneca$268
  • Bayer$177
  • Pfizer$102
  • Boehringer Ingelheim$75
  • Novo Nordisk$33
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$1,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,485 in reported general payments places this provider in the 70th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$3,009
Medicare patients
18
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$77,150
JardianceEmpagliflozin44$44,301
OzempicSemaglutide28$41,368
EliquisApixaban37$35,821
TradjentaLinagliptin41$35,139
XareltoRivaroxaban15$19,421
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$9,006
Gabapentin233$5,689
Albuterol Sulfate HfaAlbuterol Sulfate212$5,254
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$4,164
LantusInsulin Glargine,hum.Rec.Anlog17$3,684
SymbicortBudesonide/Formoterol Fumarate16$3,612
Doxycycline Monohydrate75$3,188
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,051
Levothyroxine Sodium210$2,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$75$88,44598 claims
GSKTrelegy Ellipta$726$77,15090 claims
Novo NordiskOzempic$33$41,36828 claims
PfizerEliquis$102$35,82137 claims
Johnson & JohnsonXarelto$21$19,42115 claims
AstraZenecaSymbicort$268$3,61216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,237 adult health providers in Florida.

Other adult health in Hudson

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →